SNCA and Parkinson disease: Because P47phox (i) appears as the rate-limiting factor for Nox2 activation, (ii) directly binds to DJ-1 and (iii) is phosphorylated by several kinases activated downstream of pathways activated by alpha-synuclein, it is a potentially important target for the development of therapeutic agents against PD.